Fluorescein Angiography Market To Reach $1.39 Billion By 2030

Fluorescein Angiography Market Growth & Trends

The global fluorescein angiography market size is expected to reach USD 1.39 billion by the end of 2030, expanding at a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of ophthalmic conditions such as macular degeneration and diabetic retinopathy and rapid technological advancements are some of the high impact-rendering market drivers. However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.

End-users such as hospitals and imaging centers in the country are effectively adopting AI-based fundus cameras for detecting various blindness-causing diseases. For instance, in January 2019, Deqing County hospital in Guangdong Province conducted a free consultation by featuring an AI camera codeveloped by Sun Yat-sen University and Baidu-a multinational technology company in China that offers services, including a search engine platform-to detect ocular fundus diseases. This AI fundus camera is capable of diagnosing glaucoma, diabetic retinopathy, and macular degeneration.

Despite preference of its alternatives, fluorescein angiography is often used as confirmatory test for a wide range of ophthalmic conditions. The technique provides accurate and high quality pictures which help in selecting efficient treatment regimen. In addition, the demand for tradition fluorescein angiography systems is still high in developing countries. This can be attributed to affordability and product availability.

 Request a free sample copy or view report summary: Fluorescein Angiography Market Report

Fluorescein Angiography Market Report Highlights

• Traditional fluorescein angiography dominated the market and accounted for the largest revenue share of 56.4% in 2024, attributed to the rising incidence of eye diseases, particularly diabetic retinopathy and age-related macular degeneration. 

• The age-related macular degeneration (AMD) application held the dominant position in the market, with the largest revenue share of 32.6% in 2024, owing to the increasing prevalence of this condition among the aging population. 

• The hospitals and clinics segment led the market and accounted for the largest revenue share of 63.9% in 2024 attributed to the increasing prevalence of eye diseases, particularly among the aging population. 

• The fluorescein angiography market in North America dominated the global market and accounted for the largest revenue share of 36.4% in 2024 attributed to the high prevalence of eye diseases, particularly diabetic retinopathy, which affects millions of individuals.

Fluorescein Angiography Market Segmentation

Grand View Research has segmented the global fluorescein angiography market on the basis of type, application, end use, and region:

Fluorescein Angiography Type Outlook (Revenue, USD Million, 2018 - 2030)

• Traditional Fluorescein Angiography (FA)

• Confocal Scanning Laser Ophthalmoscopy (cSLO) FA

Fluorescein Angiography Application Outlook (Revenue, USD Million, 2018 - 2030)

• Age-related Macular Degeneration (AMD)

• Diabetic Retinopathy

• Retinal Vein Occlusion

• Uveitis and Retinal Vasculitis

• Choroidal Tumors

• Others

Fluorescein Angiography End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Clinics

• Ambulatory Surgical Centers

• Others

Fluorescein Angiography Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Fluorescein Angiography Market

• Carl Zeiss Meditec, Inc.

• NIDEK Co., Ltd.

• Kowa Company Ltd.

• Topcon Medical Systems, Inc.

• Optomed Oy (Ltd.)

• CenterVue SpA

• Canon, Inc.